Premium
Suppression of malignant rhabdoid tumors through Chb‐M′‐mediated RUNX1 inhibition
Author(s) -
Daifu Tomoo,
Mikami Masamitsu,
Hiramatsu Hidefumi,
Iwai Atsushi,
Umeda Katsutsugu,
Noura Mina,
Kubota Hirohito,
Masuda Tatsuya,
Furuichi Kana,
Takasaki Saho,
Noguchi Yuki,
Morita Ken,
Bando Toshikazu,
Hirata Masahiro,
Kataoka Tatsuki R.,
Nakahata Tatsutoshi,
Kuwahara Yasumichi,
Iehara Tomoko,
Hosoi Hajime,
Takita Junko,
Sugiyama Hiroshi,
Adachi Souichi,
Kamikubo Yasuhiko
Publication year - 2021
Publication title -
pediatric blood and cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.116
H-Index - 105
eISSN - 1545-5017
pISSN - 1545-5009
DOI - 10.1002/pbc.28789
Subject(s) - medicine , runx1 , cancer research , malignancy , in vivo , targeted therapy , transcription factor , in vitro , cancer , biology , genetics , gene
Malignant rhabdoid tumor (MRT) is a rare and highly aggressive pediatric malignancy primarily affecting infants and young children. Intensive multimodal therapies currently given to MRT patients are not sufficiently potent to control this highly malignant tumor. Therefore, additive or alternative therapy for these patients with a poor prognosis is necessary. We herein demonstrated that the inhibition of runt‐related transcription factor 1 (RUNX1) by novel alkylating conjugated pyrrole‐imidazole (PI) polyamides, which specifically recognize and bind to RUNX‐binding DNA sequences, was highly effective in the treatment of rhabdoid tumor cell lines in vitro as well as in an in vivo mouse model. Therefore, suppression of RUNX1 activity may be a novel strategy for MRT therapy.